Shots:

• The IMPACT study involves assessing of Trelegy Ellipta (qd-100/62.5/25mcg) vs (ICS/LABA Relvar/Breo Ellipta (FF/VI)) (100/25mcg) & ((LAMA)/LABA Anoro Ellipta (UMEC/VI)) (62.5/25mcg) in patients with COPD
• The Expanded label approval will serve as a maintenance treatment for patients with moderate-to-severe COPD and shown effective results in comparison to ICS- LABA & LAMA. In 2017- Trelegy Ellipta has also received EU approval for this indication
• Trelegy Ellipta is a novel triple therapy inhaler- with combination of three molecules and is approved in US for airflow obstruction in patients with COPD- including chronic bronchitis and emphysema

Ref: GSK | Image: GSK